| UHC Medicaid Medical & Drug | Oncology Medication Clinical Coverage – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Ophthalmologic Complement Inhibitors – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Ophthalmologic Vascular Endothelial Growth Factor (VEGF) Inhibitors – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Parsabiv® (Etelcalcetide) – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Provider Administered Drugs – Site of Care – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Reblozyl® (Luspatercept-Aamt) – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Rebyota® (Fecal Microbiota, Live-Jslm) – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Respiratory Interleukins (Cinqair®, Fasenra®, & Nucala®) – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Review at Launch for New to Market Medications – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Rituximab (Riabni®, Rituxan®, Ruxience®, & Truxima®) – Community Plan Medical Benefit Drug Policy | 2026-04-01 |